Study Details

Citation

Kottke, M. J., Sales, J. M., Goedken, P., Brown, J. L., Hatfield-Timajchy, K., Koumans, E. H., Hardin, J. W., Kraft, J. M., & Kourtis, A. P. (2022). 2gether: A clinic-based intervention to increase dual protection from sexually transmitted infections and pregnancy in young African American females. Journal of Women’s Health. https://doi.org/10.1089/jwh.2022.0209

Program or Component Study?
Program
Program or Component Name

2gether

Show Evidence of Effectiveness
Yes
Study Rating and Explanation
High

This study received a high study quality rating because it is a low-attrition randomized controlled trial with no known issues that would suggest the findings cannot be attributed to the program

Program Information

Program Type
Clinic-based

Evaluation Setting

Evaluation Setting
Health clinic or medical facility

Study Sample

Average Age Group
14 to 17
Majority Racial/Ethnic Group
African American or Black
Sex
Young female

Research Design

Assignment Method
Randomized controlled trial
Sample Size

714

Number of Follow-Ups

4

Length of Last Follow-Up

12 months after enrollment

Year of Last Data Collection
2018

Study Findings

Result STI or HIV
Potentially favorable evidence
Result Pregnancy
Indeterminate evidence
Reviewed Studies
High-Quality Randomized Trial
Protocol Version
Version 7.0
Details

The 2gether intervention was evaluated in a randomized controlled trial implemented in a clinical setting. Participants were African American female adolescents who were not pregnant at enrollment, had vaginal sex with a male partner at least once in the previous six months, were self-reported HIV negative, were planning on staying in the study area for the study period, were not previously enrolled in the pilot study, and had a desire to avoid pregnancy for at least 12 months. A total of 1,396 adolescents were assessed, with about half being deemed ineligible; 714 adolescents were randomized, but some were subsequently determined to not be eligible because they either (1) did not complete the enrollment visit, (2) were diagnosed with HIV at enrollment, or (3) were pregnant at enrollment. This left an analytic sample of 685 participants, with 337 assigned to the treatment group and 348 assigned to the control group. Data were collected at a three-month follow-up call, a six-month follow-up visit, a nine-month follow-up call, and a 12-month final follow-up visit. In addition, data on positive STI or pregnancy tests for all participants were collected from medical records. The data collected from these follow-ups were pooled and analyzed cumulatively. The primary analytic approach for assessing program effectiveness was to estimate time to an event (positive STI test or pregnancy) using a proportional hazard model. In addition, the study presented differences in overall rates of outcomes pooled across all observed data collection events. Only the time-to-event analyses meet TPPER reporting requirements.

The study's main outcomes of interest were biologic outcomes (testing positive for chlamydia, gonorrhea, trichomonas, and pregnancy). The study showed a statistically significant and favorable effect on the time to trichomonas event (adjusted hazard ratio = 0.59; CI = [0.36, 0.94]; TPPER-calculated effect size based on prevalence rates of the outcomes = -0.27). That is, it took significantly longer for adolescents in the treatment group to experience a trichomonas event than it took for adolescents in the control group. There were no statistically significant differences observed for any of the other outcomes.

There were a number of outcomes outside the scope of review. The combined biologic outcomes were not eligible for review because they pool information across multiple measures (testing positive for STIs and pregnancy). Other outcomes outside of the scope of the review include contraceptive knowledge, contraceptive self-efficacy, STI knowledge, intentions to use a contraceptive, intentions to use condoms, and reports of verbal or physical threats from a partner.

Effect Sizes
{"0": {"ProgramName":"2gether","StudyID":"PPRER0Z23008","ManuscriptID":"PPRER0Z23008","sid":"294","Rating":"High","OutcomeName":"Chlamydia","OutcomeDomain":"STIs or HIV","OutcomeDichotomous":"Yes","SampleType":"Full sample","FUTimingMonths":"12","FUReference":"Postenrollment","MeanTreat":"0.18","MeanComp":"0.2","TpperES":"-0.067","StatSigRepEffect":"No","RepEffectFavorable":"Not significant","RepEffectMeet":"No"},"1": {"ProgramName":"2gether","StudyID":"PPRER0Z23008","ManuscriptID":"PPRER0Z23008","sid":"294","Rating":"High","OutcomeName":"Gonorrhea","OutcomeDomain":"STIs or HIV","OutcomeDichotomous":"Yes","SampleType":"Full sample","FUTimingMonths":"12","FUReference":"Postenrollment","MeanTreat":"0.07","MeanComp":"0.09","TpperES":"-0.149","StatSigRepEffect":"No","RepEffectFavorable":"Not significant","RepEffectMeet":"No"},"2": {"ProgramName":"2gether","StudyID":"PPRER0Z23008","ManuscriptID":"PPRER0Z23008","sid":"294","Rating":"High","OutcomeName":"Trichomonas","OutcomeDomain":"STIs or HIV","OutcomeDichotomous":"Yes","SampleType":"Full sample","FUTimingMonths":"12","FUReference":"Postenrollment","MeanTreat":"0.08","MeanComp":"0.12","TpperES":"-0.269","StatSigRepEffect":"Yes","RepEffectFavorable":"Yes","RepEffectMeet":"Yes"},"3": {"ProgramName":"2gether","StudyID":"PPRER0Z23008","ManuscriptID":"PPRER0Z23008","sid":"294","Rating":"High","OutcomeName":"Pregnancy","OutcomeDomain":"Pregnancy","OutcomeDichotomous":"Yes","SampleType":"Full sample","FUTimingMonths":"12","FUReference":"Postenrollment","MeanTreat":"0.12","MeanComp":"0.14","TpperES":"-0.136","StatSigRepEffect":"No","RepEffectFavorable":"Not significant","RepEffectMeet":"No"}}

NA = Not available. This means the authors did not report the information in the manuscripts associated with the studies we reviewed.

a This information was not available whenever authors did not report information for the treatment and comparison groups separately on outcome means, standard deviations, and/or sample sizes.

b Authors reported that the program effect (impact) estimate is statistically significant with a p-value of less than 0.05 based on a two-tailed test.

c For some outcomes, having less of that outcome is favorable. In those cases, an effect with a negative sign is favorable to the treatment group (that is, the treatment group had a more favorable outcome than the comparison group, on average).

d An effect shows credibly estimated, statistically significant evidence whenever it has a p-value of less than 0.05 based on a two-tailed test, includes the appropriate adjustment for clustering (if applicable), and it is not based on an endogenous subgroup.

Language directly from the program model developer or authors.